SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:
• to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
• to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
• to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)
5 mg in glass bottle
SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
Vanilloid receptor-1 (TRPV1) antagonist.
Features and Benefits
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
|assay ||≥98% (HPLC)|
|color ||white to beige|
|solubility ||DMSO: 5 mg/mL, clear|
|SMILES string ||COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1|
|InChI key ||RYAMDQKWNKKFHD-JXMROGBWSA-N|
|Gene Information ||human ... TRPV1(7442)|
RIDADR NONH for all modes of transport